The Autopsy / Case File · Overdose & Substance
The Sedative Naloxone Can't Touch
Xylazine has no reversal drug, no FDA approval for human use, and no sign of leaving the fentanyl supply.
A veterinary tranquilizer meant for horses and cattle is now detected in a rising share of fatal opioid overdoses nationwide. Naloxone can't touch it. Here's a sourced look at how it got into the supply, what it does to the people who use it, and why the standard overdose response only solves half the problem.
Join the discussion →
Xylazine was never meant for a human body. It's a non-opioid sedative, developed in the 1960s and approved only for veterinary use — horses, cattle, the occasional zoo animal that needs to hold still. It has no FDA approval for people, no established human dosing, and no antidote. For most of its history, that was a footnote. Then it started showing up, uninvited, in the same glassine bags as fentanyl.
A Different Kind of Overdose
The overdose-response playbook built over the last decade runs on one drug: naloxone. It binds to opioid receptors, kicks fentanyl or heroin off them, and restores breathing within minutes. It's cheap, it's widely distributed, and it has reversed hundreds of thousands of overdoses. It was built for a supply that was, at its core, opioids.
Xylazine breaks that model. It's an alpha-2 adrenergic agonist — it works on an entirely different receptor system than opioids do, the same class of receptor targeted by some blood-pressure medications. Naloxone has no mechanism to act on it. A person who has taken fentanyl cut with xylazine can be given naloxone, breathe again as the opioid component is reversed, and still remain unconscious, unresponsive, and sedated for hours — because the drug still suppressing their central nervous system was never the one naloxone was built to fight.
Public health guidance still tells bystanders to give naloxone anyway. That's not a contradiction — it's because fentanyl is almost always the other ingredient in the mixture, and reversing the opioid component still restores breathing, the immediate cause of death in most overdoses. Naloxone doesn't fail against xylazine so much as it only does half the job the drug supply now requires.
How Fast It Moved
Xylazine's spread through the East Coast fentanyl supply, and then the rest of the country, happened inside a few years — fast enough that the CDC's own surveillance struggled to keep pace with where it had already arrived. The first widely reported cluster was Philadelphia, where "tranq" became local slang for fentanyl cut with the sedative years before most other cities had detected it at all.
Connecticut (26.4%) and Pennsylvania (23.3%) followed close behind Maryland in the same reporting window. DEA lab data shows the trajectory didn't level off after that snapshot: xylazine's presence in seized fentanyl tablets rose fivefold, and in fentanyl powder threefold, in the years following 2020. By the time federal agencies had fully mapped the problem, it had already stopped being a regional one.
On April 12, 2023, the White House designated fentanyl adulterated with xylazine the first-ever federal "emerging drug threat" — a legal trigger that forced a government-wide response plan within 90 days.
What It Does to a Body
Xylazine's danger isn't confined to the overdose moment. People who use it repeatedly, whether they know it's in their supply or not, develop a distinctive and severe wound: necrotic skin ulcers that can appear anywhere on the body, not just at an injection site, and can affect people who smoke or snort the drug rather than inject it.
The leading clinical theory is that xylazine's vasoconstrictive properties — its tendency to narrow blood vessels — starve tissue of blood flow wherever it settles in the body, producing dead tissue that spreads outward from small sores if untreated. Case reports published in the medical literature describe wounds progressing to the point of requiring surgical debridement, and in severe cases, amputation. Wound care clinics built around the injuries typical of injection drug use — abscesses, cellulitis — are now encountering a different injury altogether, one that doesn't respond to the same treatment protocols.
Those numbers likely undercount the real exposure. Many people who test positive for xylazine at death, or in a wound clinic, never knowingly sought it out — it arrived in their supply the way fentanyl itself often does, mixed in by a trafficker rather than requested by a buyer. A person can have significant xylazine exposure and no idea the drug has a name at all.
A Withdrawal With No Playbook
Xylazine produces its own withdrawal syndrome, separate from opioid withdrawal and, by most clinical accounts, worse. Severe anxiety, agitation, profuse sweating, and rebound hypertension are common, and because the drug isn't an opioid, none of the standard medications used to manage opioid withdrawal — buprenorphine, methadone — touch the xylazine component of it.
The clinical consequence is a documented, self-reinforcing cycle: patients delay seeking wound or overdose care because they fear a hospital stay will trigger a withdrawal they know clinicians aren't equipped to manage, and patients who do seek care sometimes leave against medical advice once withdrawal symptoms begin, before treatment is complete. There is, as of this writing, no FDA-approved medication and no consensus clinical protocol built specifically for xylazine withdrawal — physicians are managing a novel syndrome with tools built for a different drug.
The Federal Response, and Its Limits
The April 2023 emerging-threat declaration required an interagency National Response Plan, released that July, covering testing capacity, treatment and wound-care protocols, data systems to track xylazine's spread, and efforts to reduce the supply of xylazine itself — most of which is diverted from the legitimate veterinary-medicine supply chain rather than synthesized illegally, since it isn't a scheduled controlled substance under federal law.
That last detail is the plan's central structural problem. Fentanyl is illegal to manufacture, sell, or possess outside a licensed medical context. Xylazine, as of this writing, is not federally scheduled at all — it's a legitimate veterinary drug that happens to also be cheap, widely available, and unregulated at the retail and wholesale level in a way fentanyl's own precursor chemicals aren't. Some states have moved to schedule it individually; there is still no uniform federal control, which means the supply-side lever public health officials would most want to pull barely exists yet.
The State Patchwork, and the Veterinarians Caught In It
Because xylazine sits outside federal drug scheduling, states have moved on their own, at different speeds and to different degrees, turning a single national drug-supply threat into a state-by-state patchwork of who can be charged with possessing it, and how seriously.
The scheduling decisions matter beyond symbolism: they determine whether a possession charge for xylazine can be prosecuted at all, and they determine how a state's own crime labs and medical examiners are required to test for it, which shapes how completely a state's own mortality data captures the problem in the first place. A state that hasn't scheduled xylazine has less legal reason to routinely screen for it in a toxicology panel, which means its own death-certificate data likely understates how present the drug already is — the same undercounting problem baked into any drug that isn't part of a standard test panel until public health officials decide it should be.
Every state that has scheduled xylazine has also had to write in an explicit exemption for licensed veterinary use, because the underlying compound is a legitimate, common surgical sedative for horses and livestock, manufactured and sold through ordinary veterinary supply channels. That's the structural bind regulators are working inside: the same chemical a large-animal vet needs on hand for a routine procedure is the one showing up, diverted, in a bag of fentanyl three states away — and a law broad enough to stop the diversion risks being broad enough to disrupt the legitimate supply chain it was never meant to touch.
And Then You're Dead
The overdose crisis was already hard to reverse when the mechanism was a single class of drug and a single antidote. Xylazine didn't replace fentanyl — it rode along with it, past the one tool built to answer for what's in the supply. Somebody dies still sedated after the naloxone worked exactly as designed, because the drug that mattered wasn't the one anyone thought to reverse.
That's it. That's the whole thing.
Sources
- 276% rise in xylazine detection among illicit-fentanyl overdose deaths (2.9% to 10.9%, Jan. 2019–June 2022), across 20 states and D.C. — CDC, "Illicitly Manufactured Fentanyl–Involved Overdose Deaths with Detected Xylazine — United States, January 2019–June 2022," MMWR, June 2023; state-level rates (Maryland 27.7%, Connecticut 26.4%, Pennsylvania 23.3%) from the same report, also released as CDC NCHS Vital Statistics Rapid Release Report No. 30, "Drug Overdose Deaths Involving Xylazine"
- DEA seizures of fentanyl-xylazine combinations in 48 of 50 states, and 2022 seizure testing showing 23% of fentanyl powder and 7% of fentanyl pills positive for xylazine — U.S. Drug Enforcement Administration, "The Growing Threat of Xylazine and its Mixture with Illicit Drugs," December 2022
- Fivefold increase in xylazine detected in seized fentanyl tablets and threefold increase in powder since 2020 — U.S. Drug Enforcement Administration, "DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine"
- April 12, 2023 designation of fentanyl adulterated or associated with xylazine as an emerging drug threat, and the July 2023 National Response Plan required under the SUPPORT Act — White House Office of National Drug Control Policy, "Fentanyl Adulterated or Associated with Xylazine Emerging Threat Response Plan," July 2023
- Xylazine's non-opioid pharmacology, naloxone's lack of mechanism against it, and clinical guidance to still administer naloxone because fentanyl is typically the co-occurring drug — National Institute on Drug Abuse, "Xylazine"
- Necrotic skin ulcers at and away from injection sites, vasoconstriction as the likely mechanism, and progression to surgical debridement or amputation in severe cases — Ehrman-Dupre et al., "Xylazine — Medical and Public Health Imperatives," New England Journal of Medicine, 2023, and "Xylazine-Induced Necrotic Skin Ulcers in a Fentanyl-Injecting Individual in South Florida: A Case Report," PMC
- 12.7% lifetime and 8.3% recent xylazine use among adults with illicit fentanyl or heroin use histories, in a national treatment-population survey, July 2022–September 2023 — CDC, "Reported Xylazine Use Among Adults Aged ≥18 Years Evaluated for Substance Use Treatment — United States, July 2022–September 2023," MMWR
- Xylazine withdrawal syndrome and its documented barrier to sustained care — Philadelphia Department of Public Health, "Recommendations for Caring for Individuals with Xylazine-Associated Wounds"
- State-by-state xylazine scheduling status as of March 2024 (seven states scheduled, at Schedule I through V, all with veterinary-use exemptions) — Legislative Analysis and Public Policy Association, "Novel Psychoactive Substances: Xylazine — Update," March 2024
Photo: "NaloxoneKit.jpg" by James Heilman, MD, via Wikimedia Commons (CC BY-SA 4.0).
Comments
Loading…